We have some announcements to make about the HAE Canada Board of Directors. The 2022-2023 Board of Directors was elected at our Annual General Meeting in November. Following the meeting, the Board elected the executive

You deserve to live your best life. However, living with HAE can be difficult, even between attacks. Takeda Inc. is introducing a new, comprehensive resource designed to help you assess the impact HAE has on

Thank you to the amazing HAE Community here in Canada - Canada won the Virtual 2020 HAE Global Walk; an annual event organized by the HAE International team. Many people from different parts of the

HAE Canada is excited to announce that our new and improved website officially went live today, May 22, 2020. This project was made possible through our partnership with HAE International (HAEi), which is graciously hosting

HAEGARDA and TAKHZYRO are now available in Canada. Please talk to your HAE specialist about access. Thank you Canadian Blood Services (CBS) for a very collaborative, informative and team building HAE Forum. The care for

For HAE Day 2020, HAE Canada wants to celebrate! To honour the day we have two BIG announcements: 1) Our website received a facelift! We hope our members find the updated content and new

It’s time, once again, for HAE Canada to please ask you to take out your walking shoes and participate in the virtual HAE Global Walk arranged by HAE International. HAE Canada is encouraging our members,

HAE Canada continues to remain focused on the health and well-being of patients with hereditary angioedema, and other related angioedema, in Canada. We would like to share what information we have gathered regarding the COVID-19

We are thrilled to let the HAE community know that HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) is now available to HAE patients in Quebec. HAEGARDA is a subcutaneous C1 esterase inhibitor (C1-INH) therapy indicated for